Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cannabidiol · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Cannabidiol | DRUG | Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant. |
Cannabidiol is being studied for the treatment of Menstrual Discomfort, a condition involving pain and other symptoms associated with the menstrual cycle. It is an investigational small molecule in Phase 2 clinical development, and it has not been approved by the FDA for this use.
Cannabidiol is a small molecule being investigated for Menstrual Discomfort. Its specific molecular target has not been disclosed in the available information, so its mechanism of action in this context is not specified.
Cannabidiol is being developed by Canopy Growth Corporation, a company whose common shares trade under the ticker CGC. The company is conducting clinical research to evaluate the drug's effects on Menstrual Discomfort.
Cannabidiol is in Phase 2 clinical development for Menstrual Discomfort. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy.
Cannabidiol has one completed clinical trial, NCT05679830, titled 'The Effects of CBD Isolate on Menstrual-Related Symptoms.' This Phase 2 study enrolled 33 participants and was an uncontrolled, non-randomized, open-label trial. The trial is completed, and no active trials are currently listed.
Cannabidiol is commonly known as CBD, a shorthand often used in consumer and research contexts. In this clinical development program, the drug is referred to as Cannabidiol, and the trial specifically evaluates a CBD isolate formulation for menstrual-related symptoms.